Journal
BIOCHEMICAL PHARMACOLOGY
Volume 152, Issue -, Pages 315-326Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2018.04.009
Keywords
Chromogranins; Chromogranin-A derived peptides; Mucosal drug action; Gut hormones; Colitis
Categories
Funding
- Canadian Foundation for Innovation
- Crohn's and Colitis Canada
- Research Manitoba
- Children's Hospital Research Institute of Manitoba
- Natural Sciences and Engineering Research Council
- Canadian Institutes of Health Research
- University of Manitoba
- Health Science Centre Foundation (HSCF)-Mindel and Tom Olenick Research Excellence Award in Immunology
- MITACS Accelerate Program
Ask authors/readers for more resources
The gastrointestinal tract is the largest endocrine organ that produces a broad range of active peptides. Mucosal changes during inflammation alter the distribution and products of enteroendocrine cells (EECs) that play a role in immune activation and regulation of gut homeostasis by mediating communication between the nervous, endocrine and immune systems. Patients with inflammatory bowel disease (IBD) typically have altered expression of chromogranin (CHG)-A (CHGA), a major soluble protein secreted by EECs that functions as a pro hormone. CHGA gives rise to several bioactive peptides that have direct or indirect effects on intestinal inflammation. In IBD, CHGA and its derived peptides are correlated with the disease activity. In this review we describe the potential immunomodulatory roles of CHGA and its derived peptides and their clinical relevance during the progression of intestinal inflammation. Targeting CHGA and its derived peptides could be of benefit for the diagnosis and clinical management of IBD patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available